Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Adds MMR Vaccine To Export Ban List

Parallel Traders Say List Is Non-Transparent & Misdirected

Executive Summary

There are now 31 medicines on the UK’s list of products that cannot be parallel exported to other European Economic Area countries as part of government efforts to tackle drug shortages. The parallel trade industry has attacked the initiative for lack of transparency.

You may also be interested in...



EU Parallel Trade ‘Alleviates Shortages’ Says New EAEPC President

Parallel traders play a major role in injecting competition into the EU pharmaceutical market place and alleviating drug shortages, says Kohlpharma’s Jörg Geller, who has just taken over at the helm of the parallel distributors’ representative body in Europe. 

Belgian Court Overturns Parallel Export Ban

A ban on the parallel exporting of medicines from Belgium did not achieve the desired objective of preventing drug shortages, and was also against EU rules, the Constitutional Court has ruled.

EMA Identifies Potential Sources Of Nitrosamine Contamination

As companies evaluate scores of products for the possible presence of nitrosamine impurities, the EU regulator has listed potential sources of contamination identified to date to help sponsors develop a risk-based approach for their evaluations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel